Medday Pharmaceuticals
Medday Pharmaceuticals is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Medday Pharmaceuticals.
Medday Pharmaceuticals is a company.
Key people at Medday Pharmaceuticals.
Key people at Medday Pharmaceuticals.
MedDay Pharmaceuticals is a biopharmaceutical company founded in 2011, specializing in treatments for nervous system disorders with high unmet medical needs, particularly through research into brain metabolism pathways.[1][2] It targets neurological diseases like multiple sclerosis (MS), autism, and Alzheimer’s, with its most advanced candidate being MD1003 (high-dose biotin) for primary and secondary progressive MS, though a key Phase III trial failed in 2020; the company also pursues MD-1103 for autism and MD-1105 for Alzheimer’s.[1][2][4] MedDay serves patients with rare inborn errors of metabolism and neurodegenerative conditions, addressing gaps in therapies by leveraging expertise in neurometabolism, and raised €42 million from investors like Sofinnova Partners to fund development.[2]
MedDay was founded in 2011 by Frédéric Sedel, MD, PhD—a leading neurologist and neuroscientist specializing in metabolic disorders—and Guillaume Brion, MD, an entrepreneur with 25 years in drug development and clinical research.[1][2] The idea emerged from Sedel's clinical insights into brain metabolism and Brion's pharmaceutical experience, creating a biotech firm focused on neurometabolism for neurological diseases.[2] Key milestones include €8 million Series A in 2013, the first US/EU patent in 2014, €34 million Series B in 2016, and acquiring Profilomic SA in 2017 to bolster its SPECMET metabolomics platform; however, the 2020 SPI2 Phase III failure for MD1003 marked a setback.[2]
The name "MedDay" draws from the "mayday" distress signal, symbolizing a call for help ("m’aider" in French) in treating unmet needs.[2]
MedDay rides the wave of precision medicine in neurology, targeting metabolism pathways overlooked in traditional neurodegeneration research, amid rising demand for therapies in progressive MS (affecting ~1 million globally) and aging-related diseases like Alzheimer’s.[1][3] Timing aligns with post-2020 biotech shifts toward metabolic modulators, fueled by failures in antibody-based MS treatments and growing interest in biotin/orphan drug repurposing.[2][4] Market forces favoring it include EU-based incentives for rare diseases, VC support for neuro-biotech (e.g., Sofinnova's Life Sciences focus), and a fragmented progressive MS market lacking disease-modifying options.[2] It influences the ecosystem by validating neurometabolism as a novel paradigm, potentially inspiring similar metabolic approaches in rivals.
Post-2020 SPI2 failure, MedDay faces pipeline uncertainty with MD1003 discontinued and others pending, likely pivoting to Alzheimer’s/autism candidates amid biotech funding caution.[2][4] Trends like AI-driven metabolomics and combo therapies could revive momentum, especially if MD-1105 advances. Its influence may evolve from MS pioneer to niche neurometabolism player, contingent on trial successes—watch for partnerships to bridge expertise gaps and scale globally.[1][2] This "mayday" call for brain health innovation remains vital in an era of unmet neuro needs.
